Summary:

In this episode, Nathaniel Schuster, MD, Professor and Medical Director of the Center for Pain Management at UC San Diego Health, explores the potential role of cannabinoid therapy in migraine care. Join us as Dr. Schuster shares insights into the benefits, limitations, and practical considerations of this approach, and discusses his latest research on vaporized cannabis for acute migraine treatment, including clinical trial findings and future directions.

Key Topics:

Overview of the first placebo-controlled trial of vaporized cannabis for migraineThe scientific rationale behind using THC and CBD in migraine treatmentStudy design: crossover methodology, dosages, and use of research-grade cannabisPrimary and secondary outcomes: pain relief, pain freedom, and bothersome symptomsSurprising findings on nausea, photophobia, and sound sensitivity improvementsSide effects, safety profile, and optimal dosing strategiesPractical considerations: vaporized vs. oral formulations and patient preferencesRecommendations for patients with refractory migraines considering cannabinoid therapyFuture research directions: preventive treatments and guidelines incorporation

Timestamps:

00:03 – Introduction to Cannabis Study

00:56 – Welcome Dr. Nathaniel Schuster

01:41 – Dr. Schuster's Background

02:29 – Understanding Migraine

03:18 – Current Migraine Treatments

04:14 – Defining Migraine

05:11 – Genetic Factors in Migraine

06:01 – Cannabis as a Treatment Option

07:54 – Study Hypothesis and Design

10:45 – Study Design Details

13:41 – Crossover Study Explanation

16:51 – Study Findings

20:36 – Most Bothersome Symptom Freedom

23:01 – Side Effects and Safety

26:40 – Participant Demographics

28:34 – Future Research Directions

30:00 – Practical Considerations

32:09 – Advice for Migraine Patients

33:50 – Safety Considerations

34:03 – Closing Remarks

⁠Read Dr. Schusters's study.

Bio:

Dr. Nathaniel Schuster is a pain and headache neurologist and is Professor and Medical Director at the UC San Diego Center for Pain Management. He has served as Treasurer of the American Academy of Pain Medicine, Senior Vice President of the World Headache Society, and as Vice Chair of the Guidelines Committee for the International Pain and Spine Intervention Society. He has received the American Academy of Pain Medicine’s Rollin “Mac” Gallagher Award, the American Academy of Pain Medicine’s Distinguished Service Award, the American Headache Society’s Harold G. Wolff Award, the International Pain and Spine Intervention Society’s Outstanding Volunteer Award, and the Migraine Research Foundation’s Impact Award. He is section editor for the Neuropathic Pain section for the journal Pain Medicine. He graduated from University of Michigan Medical School and completed a neurology residency at UCLA, headache fellowship at Montefiore Headache Center, and pain fellowship at Massachusetts General Hospital. He conducted the first placebo-controlled trial of cannabinoids for acute migraine and his ongoing research includes clinical trials studying treatments for migraine and neuropathic pain.